Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00691769|
Recruitment Status : Completed
First Posted : June 5, 2008
Last Update Posted : November 6, 2017
|Condition or disease|
|Central Centrifugal Scarring Alopecia Lichen Planopilaris Discoid Lupus Erythematosus|
|Study Type :||Observational|
|Actual Enrollment :||8 participants|
|Official Title:||Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia|
|Actual Study Start Date :||April 26, 2006|
|Primary Completion Date :||November 26, 2012|
|Study Completion Date :||November 26, 2012|
CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.
- To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia (CCSA), lichen planopilaris (LP) and discoid lupus erythematosus (DLE) and in healthy controls. [ Time Frame: 8 weeks ]
- To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia before and after treatment with intralesional and topical steroids. [ Time Frame: 8 weeks ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00691769
|United States, North Carolina|
|Wake Forest University Health Sciences Dermatology|
|Winston-Salem, North Carolina, United States, 27157|
|Principal Investigator:||Amy McMichael, MD||Wake Forest University Health Sciences|